The Harvard AIDS Initiative

The Harvard T.H. Chan School of Public Health AIDS Initiative is dedicated to research and education to end the AIDS epidemic in Africa and developing countries. Since 1988, HAI has been at the forefront of HIV/AIDS laboratory research, clinical trials, education, and leadership.

The Harvard AIDS Initiative: the Movie

What starts as a story of death and ignorance becomes a chronicle of discovery and success. To mark its 25th anniversary, the Harvard AIDS Initiative created a short video outlining major accomplishments and the work that remains to be done. Watch the movie on Vimeo


 The Botswana Harvard AIDS Institute Partnership

The Botswana Harvard AIDS Institute Partnership (BHP) was established in 1996 and is an independent, local organization in Botswana. BHP is dedicated to the fight against HIV/AIDS and emerging public health challenges through collaborative research, education, capacity building, and community engagement.


 The African Comprehensive HIV/AIDS Partnerships

The African Comprehensive HIV/AIDS Partnerships (ACHAP) was created in 2000 as a public-private partnership (PPP) between the Government of Botswana, the Bill & Melinda Gates Foundation and The Merck Company Foundation. ACHAP has now transitioned into an independent organization with a broader health mandate and wider geographic focus, continuing to build on its core competencies in the field of HIV/AIDS and related health conditions. – See more about ACHAP here.

  • ACHAP Video: To learn more about ACHAP and the work done by the organization, watch this short film produced by The Health Channel.
  • A Second ACAHP Video: In launching the second phase of ACHAP in 2011, a promotional video was created.


The Elizabeth Glaser Pediatric AIDS Foundation

Started by three Moms in 1988, the Elizabeth Glaser Pediatric AIDS Foundation seeks to end pediatric HIV/AIDS through research, advocacy, and prevention and treatment programs.

  • Project HEART Video: Through the leadership and support of the President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Centers for Disease Control and Prevention (CDC), the Foundation led the implementation of Project HEART (Help Expand Antiretroviral Therapy to children and families). Through the program, more than 1 million men, women, and children received HIV care and support, and more than half a million people started ART. By 2010, 1 out of every 10 PEPFAR-supported ART patients in sub-Saharan Africa received their treatment through Project HEART. In addition, more than 2.5 million pregnant women received HIV counseling and testing, and more than 66,500 HIV infections were averted in children through the provision of PMTCT (prevent mother-to-child transmission) services. Learn more about this 5 country program in this short video,  the Project HEART Video …

STF Name and Logo

In 1999, a bold program was launched in Southern Africa by the Bristol-Myers Squibb Foundation entitled “Secure the Future”. As noted by Dr. Richard Marlink, who helped advise the creation and implementation of the effort, “Secure the Future really raised the bar for AIDS funding. At the time of its launch, the US Government’s entire overseas AIDS effort was much less that the $100 million now being committed by BMS/ Secure the Future.”

Now in its second decade, the work of “Secure the Future” is described at www.securethefuture.com.

On the occasion of its 10 year anniversary, a short film was created to outline the impact of the program, Secure The Future: 10th Anniversary Film, 1999 – 2009

In the film, we hear from a few of those involved in “Secure the Future”:

  • Ms. Phangisile Mtshali, Director, Bristol-Myers Squibb Foundation, Southern Africa
  • Dr. Richard Marlink, Harvard University and Secure the Future Technical Advisory Board
  • Dr. Peter Piot, Head of UNAIDS
  • Professor Souleymane Mboup, Hopital LeDantec, Dakar and Secure the Future West Africa Advisory Board
  • Ms. Grace Mnguni
  • Dr. Mark Kline, Baylor College of Medicine and Secure the Future Technical Advisory Board
  • Mr. John Damonti, President, Bristol-Myers Squibb Foundation